These findings suggest that PEG-PBAE/pGBA1 may serve as a viable DMT that addresses multiple mechanisms of lysosomal dysfunction caused by GBA1 gene mutations or mutation-free reduction of GCase activity, offering more than simple symptomatic relief for a broad PD population. Here, GBA1 is linked to Parkinson disease.